The FDA has approved a type 2 diabetes medication for the reduction of risk of end-stage kidney disease and cardiovascular events in adults with type 2 diabetes and diabetic kidney disease.
The FDA has approved a new option for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children aged 2 years and older.
The FDA has expanded the approval a new option for the treatment of adults and children aged 12 years and older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6 infection and compensated cirrhosis who are treatment-naïve.
The FDA has approved Jynneos, a new live, non-replicating vaccination for the prevention of smallpox and monkeypox in adults aged 18 years and older who are at high risk for the diseases.
The FDA has approved the first glucagon-like peptide receptor protein treatment in the US that is not given via injection.
The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.
After 4 clinical trials showed the treatment decreased daily “off” time, the FDA approved this new add-on therapy for adults with Parkinson disease.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.